In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Heat Biologics, Inc.. Trade Record

NASDAQ:HTBX Heat Biologics, Inc. stock gains 10.47% Exit Sep 29, 2017 a Trade Record by priceseries

Trade Chart
Trade Chart HTBX Sep 12, 2017, priceSeries
About Heat Biologics, Inc.

Heat Biologics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel allogeneic off-the-shelf cellular therapeutic vaccines for a range of cancers and infectious diseases in the United States. The company develops its products based on T cell-stimulating platform technologies, including immune pan-antigen cytotoxic therapy, a platform technology designed to educate and stimulate the immune system against specific disease targets, such as cancer cells; and combination pan-antigen cytotoxic therapy, a platform technology that combines a pan-antigen T cell activating vaccine and a T cell co-stimulator in a single product. Its product candidates include viagenpumatucel-L (HS-110) that is in Phase 2 clinical trials for the treatment of non-small cell lung cancer; and vesigenurtacel-L (HS-410), which is in Phase 1b clinical trials for the treatment of non-muscle invasive bladder cancer. The company was founded in 2008 and is based in Durham, North Carolina.

Trade Information
Trade Type
LONG
ReliabilityScore™
96.36
Entry Date
Sep 12, 2017
Entry Price
5.70
Sell Date
Sep 29, 2017
Sell Price
6.30
Net Gain
10.47%
Hold Time
13 Trading Days